The digital transformation of quality-by-design assessment workflows can improve efficiency, reduce human errors, and facilitate integration within a much broader digital ecosystem.
Phil Borman
Advertisement
Phil Borman*, phil.j.borman@gsk.com, is director and senior fellow, QbD and digital platforms, medicines development and supply at GSK, Stevenage, UK.
Articles by Phil Borman
Advertisement
Latest Updated Articles
Digitalization of QbD Risk AssessmentsMarch 15th 2024
Advertisement
Advertisement
Trending on BioPharm International
1
Regeneron's Libtayo Earns CHMP Nod for Expanded EU Dosing
2
Nuravax Alzheimer Vaccine AV-1959R Earns FDA Fast Track Designation
3
Roche, Hansoh Sign Second ADC Pact Covering Preclinical and Roche-Selected Targets
4
Nano24's Inhaled EXO-CD24 Cuts ARDS Mortality in Phase 2b Trial
5